

Influenza Vaccine Information, by Age Group - United States, 2017-18 Influenza Season

| Trade Name | Manufacturer | Presentation | Mercury/Ovalbumin Content (μg per 0.5 mL dose) | Age Group | Route |
|---|--|--|--|--|-----------------|
| Inactivated influenza vaccines, quadrivalent (IIV4s), standard-dose[†] | | | | | |
| Afluria Quadrivalent | Seqirus | 0.5 mL prefilled syringe | 0.0 | ≥ 18 years | IM [§] |
| | | 5.0 mL multi-dose vial | 24.5 | ≥ 18 years via needle; 18 - 64 years via jet injector | IM |
| Fluarix Quadrivalent | GlaxoSmithKline | 0.5 mL prefilled syringe | 0.00 | ≥ 3 years. | IM |
| FluLaval Quadrivalent | ID Biomedical Corporation of Quebec (distributed by GSK) | 0.5 mL prefilled syringe | 0.00 | ≥ 6 months | IM |
| | | 5.0 mL multi-dose vial | <25.0 | | |
| Fluzone Quadrivalent | Sanofi Pasteur | 0.25 mL prefilled syringe | 0.0 | 6 - 35 months | IM |
| | | 0.5 mL prefilled syringe | 0.0 | ≥ 3 years | |
| | | 0.5 mL single dose vial | 0.0 | ≥ 3 years | |
| | | 5.0 mL multi-dose vial | 25 | ≥ 6 months | |
| Inactivated influenza vaccine, quadrivalent (ccIIV4), standard-dose,[†] cell cultured-based | | | | | |
| Flucelvax Quadrivalent | Seqirus | 0.5 mL prefilled syringe | 0.0 | ≥ 4 years | IM |
| | | 5.0 mL multi-dose vial | 25.0 | | |
| Inactivated influenza vaccine, quadrivalent (IIV4), standard-dose, intradermal[¶] | | | | | |
| Fluzone Intradermal Quadrivalent | Sanofi Pasteur | 0.1 mL prefilled microinjection system | 0.0 | 18-64 years | ID** |
| Inactivated influenza vaccines, trivalent (IIV3s), standard-dose[†] | | | | | |
| Afluria | Seqirus | 0.5 mL prefilled syringe | 0.0 | ≥ 5 years | IM |
| | | 5.0 mL multi-dose vial | 24.5 | ≥ 5 years via needle; 18-64 years via jet injector | |
| Fluvirin | Seqirus | 0.5 mL prefilled syringe | ≤ 1 | ≥ 4 years | IM |
| | | 5.0 mL multi-dose vial | 25 | ≥ 4 years | |
| Adjuvanted inactivated influenza vaccine, trivalent (aIIV3), [†] standard-dose | | | | | |
| Fluad | Seqirus | 0.5 mL prefilled syringe | 0.0 | ≥ 65 years | IM |
| Inactivated influenza vaccine, trivalent (IIV3), high-dose^{§§} | | | | | |
| Fluzone High-Dose | Sanofi Pasteur | 0.5 mL single dose prefilled syringe | 0.0 | ≥ 65 years | IM |
| Recombinant influenza vaccine, quadrivalent (RIV4) ^{¶¶} | | | | | |
| Flublok Quadrivalent | Protein Sciences | 0.5 mL prefilled syringe | 0.0 | ≥ 18 years | IM |
| Recombinant influenza vaccine, trivalent (RIV3) ^{¶¶} | | | | | |
| Flublok | Protein Sciences | 0.5 mL single dose vial | 0.0 | ≥ 18 years | IM |

Abbreviations: ACIP = Advisory Committee on Immunization Practices; ID = intradermal; IM = intramuscular

† Standard dose intramuscular IIVs contain 15 µg of each vaccine HA antigen (45 µg total for trivalents and 60 µg total for quadrivalents) per 0.5 mL dose.

§ For adults and older children, the recommended site for intramuscular influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.

¶ Quadrivalent inactivated influenza vaccine, intradermal: a 0.1-mL dose contains 9 µg of each vaccine HA antigen (36 µg total).

** The preferred injection site is over the deltoid muscle. Fluzone Intradermal Quadrivalent is administered per manufacturer's instructions using the delivery system included with the vaccine.

§§ High-dose IIV3 contains 60 µg of each vaccine antigen (180 µg total) per 0.5 mL dose.

¶¶ RIV contains 45 µg of each vaccine HA antigen (135 µg total for trivalent 180 µg total for quadrivalent) per 0.5 mL dose.

Adapted from **Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017–18 Influenza Season**. The full article is available [here](#).